BioNeutral Group, Inc. Announces Company Shareholder Update
January 15 2014 - 7:45AM
Marketwired
BioNeutral Group, Inc. Announces Company Shareholder Update
NEWARK, NJ--(Marketwired - Jan 15, 2014) - BioNeutral Group,
Inc. (OTCBB: BONU) (OTCQB: BONU)
Dear Shareholder,
Last month we released to you the news of two of our channel
partners, ProSell Sales Representatives and BioTech Medical, Inc.
for the industrial and health care segments of our relevant
marketplaces. As we mentioned then, we are excited about these
relationships and look forward to the potential for these
professionally managed organizations. Both organizations are
off to a good start. Within the industrial segment, our Ygiene™
offers unique efficacy properties over existing products for mold
remediation, and most recently ProSell is developing relationships
around the country with local owners of maintenance supply outlets
that cater to mold contractors. In the health care market
segment BioTech Medical is beginning to make important inroads as
well.
During the fourth quarter of last year, we were focused on the
upfront training and initial development of these two organizations
as well as developing new ones, news of which we should be
releasing shortly.
Our focus for the first half of 2014 will be to continue to
expand our selling effort to include additional sales partners as
well as additional market segments. In that regard, we are
engaged in active discussions with other potential independent
selling organizations as well, both here at home and abroad.
Along with adding to our selling organizations, we will in 2014
be conducting additional testing to improve our product label
claims for Ygiene™ to broaden Ygiene's market potential by
extending its reach and heightening its
competitiveness. Lastly we plan in the coming year to begin to
explore additional opportunities for our Ogiene™ line.
In conclusion, while our sales in 2013 were sparse, we gained
the important visibility to begin to attract the highly qualified
partners necessary in order to penetrate many of these relatively
long lead time, and in the health care market particularly,
organizationally complex organizations. Side by side with our
partners, our overall plan for '14 is to broaden our reach into our
markets by multiples by leveraging the relationships and awareness
we built in 2013 and adding to them. We will continue to
report our progress in these areas as it occurs
Thank you for your support in 2013 and we look forward to it in
the future as well.
About BioNeutral Group, Inc. Headquartered in Newark, New
Jersey, BioNeutral Group, Inc., is a specialty technology-based
life-science company that has developed a technology platform that
neutralizes harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi
and spores. BioNeutral's products, YGIENE™ and OGIENE™ kill germs
and clean surfaces with a dramatic increase in speed and power over
their rivals in the marketplace. BioNeutral's proprietary platform
technology has been proven effective in surface, water and airborne
applications. Its antimicrobial line of products under the YGIENE™
brand have been approved by the EPA for sale in the United States
and has previously been approved for sale in Germany and it is also
permitted to be sold in the UK, France and Sweden. Auto Neutral is
a registered trademark of BioNeutral Group, Inc. For more
information on BioNeutral, including a listing of company products,
leadership and background please visit www.bioneutral.com.
Find us on Facebook:
http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains
certain "forward-looking statements" relating to the business of
the Company and its subsidiary companies. These forward-looking
statements are often identified by the use of forward-looking
terminology such as "believes," "expects" or similar expressions.
Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially
different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. The Company's actual results could differ
materially from those anticipated in these forward-looking
statements as a result of a variety of factors, including those
described in the Company's filings with the Securities and Exchange
Commission. BioNeutral routinely tests its formulations against
those of its competitors. The results are published to let
shareholders know how the Company's technology compares with known
formulations in the market place. Any product claim for
antimicrobial activity requires approval from the EPA or FDA,
depending upon where and how the formulations are used. The EPA has
approved and registered the Company's data and findings specific to
YGIENE-206. BioNeutral's antimicrobial formulations will be
marketed under the brand name YGIENE™ and are available for sale in
the United States.
CONTACT: FOR THE COMPANY: Mark Lowenthal CEO BioNeutral Group,
Inc. +1-973-577-8003